Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

/in /by

– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max –

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’

/in /by

TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings 

TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

/in /by

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 9:45 a.m. Eastern Time in NYC.

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

/in /by

– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement –

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

/in /by

TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024.

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

/in /by

– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 –

Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA

/in /by

– Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers –

Profound Medical Announces Second Quarter 2024 Financial Results

/in /by

TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

/in /by

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024.

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

/in /by

TORONTO, July 11, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (CMS) has issued its proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective January 1, 2025.